The UK Medicines and Healthcare products Regulatory Agency previously confirmed the asset’s safety and efficacy.
Osaka Metropolitan University researchers analyzed the incidence in Japan of COVID-19-associated pulmonary aspergillosis ...
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
No longer a far-off futuristic idea, artificial intelligence technology has seen its popularity skyrocket in recent years. | ...
Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...
The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback